Regenerative Medicines And Advanced Therapies: Progress, Problems And Promise

The Alliance for Regenerative Medicine’s Q3 report illustrates just how far the sector has come in the 10 years since the organization’s founding. The number of therapies in the pipeline has ballooned, in parallel with financing for development activities.

IV1912_Genetic Engineering_1179311608_1200.jpg
• Source: Shutterstock

Queries around the viability of cell, gene and tissue engineering technologies have been mostly put to rest, now the focus is on how best to harness the huge potential these therapies offer.

The Alliance for Regenerative Medicines (ARM) was founded in 2009 with just 25 members. Its goal is to foster the...

More from Innovation

More from In Vivo